Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26N2O3 |
Molecular Weight | 354.4427 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@H](C(=O)OC)[C@@]1([H])C[C@]3([H])N(CCC4=C3NC5=CC=CC=C45)C2
InChI
InChIKey=BLGXFZZNTVWLAY-DKJBZYCGSA-N
InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19-/m0/s1
Molecular Formula | C21H26N2O3 |
Molecular Weight | 354.4427 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Corynanthine is one of the two diastereomers of yohimbine (the other is alpha-yohimbine). Corynanthine is an antagonist of the alpha-1, alpha-2A and alpha-2C adrenergic receptors showing greater selectivity for the alpha-1 adrenergic receptor. Corynanthine was tested as the active ingredient of eye drops in a small clinical trial for Ocular hypertension where formulations of 2% and 5% demonstrated relief of symptoms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35348|||B0ZBD9|||Q6RUJ8 Gene ID: 148.0 Gene Symbol: ADRA1A Target Organism: Homo sapiens (Human) |
562.0 nM [Kd] | ||
Target ID: P08913 Gene ID: 150.0 Gene Symbol: ADRA2A Target Organism: Homo sapiens (Human) |
5.1 null [pKd] | ||
Target ID: P22086 Gene ID: 24175.0 Gene Symbol: Adra2c Target Organism: Rattus norvegicus (Rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1356570 |
232.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2862619
10 symmetrically ocular hypertensive patients were treated with a single drop of 1%, 2% and 5% corynanthine solution. The 1% solution showed no effect while the 2% solution reduced IOP for at least 8 hours and the 5% solution showed a significant reduction in IOP in both eyes.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1356570
The binding constants obtained for 26 compounds (including, corynanthine) were determined by the 3-curve approach. Of these compounds WB4101, corynanthine, rauwolscine, yohimbine, ARC 239 and prazosin were found to be clearly alpha2C-selective; their electivites ranging from 16 to 30 fold (Kd for corynanthine = 232 nM). Radioligand binding was performed in 150 uL of 1 mM EDTA, 100 uM Gpp(NH)p (guanyl-5'-yl-imido-diphos-phate), 140 mM NaCl, 33 mM Tris-Cl, pH 7.5 with [3H]-MK912 and drugs for 1 h at 25°C and then filtering and washing on Whatman GF/C filters.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:34:49 GMT 2023
by
admin
on
Sat Dec 16 06:34:49 GMT 2023
|
Record UNII |
F5Z7C9RK8U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB13474MIG
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
m3805
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
407306
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
92766
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
100000079831
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
F5Z7C9RK8U
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
DTXSID401317915
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
207-590-0
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
Corynanthine
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY | |||
|
483-10-3
Created by
admin on Sat Dec 16 06:34:49 GMT 2023 , Edited by admin on Sat Dec 16 06:34:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |